No. 1 OncoRx  Testing Company In Hyderabad - GenepoweRx
                     Global Standard Testing in Oncology Now in India
ONCORx helps you better predict response or resistance to 
targeted- and immuno- therapies for more advanced cancer 
patients as compared to traditional molecular testing.
1. Why ONCORX?
ONCORx is testing solid tumours that uses next-generation sequencing (NGS) to detect the 
four alterations known to drive cancer growth: 
1. SNP
2. InDels (Insertions and deletions)
3. Copy number Variants (CNVs),
4.  Rearrangements or fusions. 
2. How is ONCORx different from single-gene or “hot spot” testing?
Single Marker or Hotspot Mutation testing can detect only one alteration where in ONCORx 
can provide insights on all four alterations. 
In other words, Single gene and hotspot testing do not look as deep or as wide as ONCORx.
3. Why ONCORx is superior to currently existing products?
Compared to Foundation one/Datar/Core/Lal Path labs, ONCORx is validated through 
World’s only FDA approved database developed by collecting longitudinal data over 20 
years by clinicians/Oncologists from Memorial Sloan Kettering Cancer Centre.
ONCORx also provides partnership opportunity to develop dataset, 24/7 customer care 
representative.
4. What if there is no FDA approved targeted therapy for the tumor 
sample?
ONCORx will provide best second line options for the patients as per NCCN guidelines. We 
will also provide with clinical trial match for the patient to enroll in leading institutions 
globally.
BIOMARKERS FDA-APPROVED THERAPY
Non-Small Cell Lung Cancer
EGFR exon 19 deletions & EGFR exon 21 Gilotrif® (afatinib), Iressa® (gefitinib), 
L858R alterations Tagrisso® (osimertinib), or Tarceva® (erlotinib)
EGFR exon 20 T790M alterations Tagrisso® (osimertinib)
ALK rearrangements Alecensa® (alectinib), Alunbrig® (brigatinib)  
Xalkori® (crizotinib), or Zykadia® (ceritinib)
BRAF V600E Tafinlar® (dabrafenib) in combination with 
Mekinist® (trametinib)
MET single nucleotide variants (SNVs) and TabrectaTM (capmatinib)
indels that lead to MET exon 14 skipping
Breast Cancer
ERBB2 (HER2) amplification Herceptin® (trastuzumab), Kadcyla® (ado-
trastuzumab-emtansine), or Perjeta® 
(pertuzumab)
PIK3CA C420R, E542K, E545A, E545D Piqray® (alpelisib)
[1635G>T only], E545G, E545K, Q546E, Q546R, 
H1047L, H1047R, and H1047Y alterations
Colo Rectal Cancer
KRAS wild-type (absence of mutations in Erbitux® (cetuximab)
codons 12 and 13)
KRAS wild-type (absence of mutations in Vectibix® (panitumumab)
exons 2, 3, and 4) and NRAS wild type 
(absence of mutations in exons 2, 3, and 4)
Ovarian Cancer
BRCA1/2 alterations Lynparza® (olaparib) or Rubraca® (rucaparib)
Prostate Cancer
Homologous Recombination Repair (HRR) Lynparza® (olaparib)
gene (BRCA1, BRCA2, ATM, BARD1, BRIP1, 
CDK12, CHEK1, CHEK2, FANCL, PALB2, 
RAD51B, RAD51C, RAD51D and RAD54L) 
alterations
All Solid Tumors
TMB ≥ 10 mutations per megabase Keytruda® (pembrolizumab)
NTRK1/2/3 fusions Vitrakvi® (larotrectinib)
FOUNDATION ONE CDx GENEPOWERX ONCORx
Targeted Genes and 325 Oncogenes NGS 325 Oncogenes NGS sequencing of 
Technology sequencing of FFPE samples FFPE samples
SNP/INDEL/CNV YES YES
Gene Fusions and YES YES
Rearrangements
Genomic Signatures  YES YES
TMB and MSI
Analytics and Self-developed pipelines, Partnered with MSK's Precision 
Reporting FDA recognition for the Oncology Knowledge Base only FDA 
process recognised Database for 127 cancer 
types and 108 FDA approved drugs.
Specific report for NO YES* Extensive Scientific literature 
Indian origin review on Published material specific 
population for Indian population.
Research Opportunity NO YES* ONCORx team is partnering with 
Institutions, oncologists to build EHR 
solutions to develop longitudinal 
meaningful DATA.
Guidelines Only FDA Approved Targeted Along with FDA Approved targeted 
treatments are reported treatments, NCCN guidelines are 
included. (Data proven Best second line 
treatments are recommended)
Further Support NO YES* Tumour expression studies 
including Whole transcriptome 
sequencing, Germline sequencing by 
offering counselling for inherited 
mutations for family members is 
offered as per Oncologist request.
Turn Around time 21 Working days 21 Working days
Sample Requirement/ FFPE sample with minimum Initial quality measure is performed in 3 
Quality confirmation 20ng genetic material. days and processed further only if 
protocols Minimal refund if quality of sample meets ONCORx standards.
sample is poor
Price INR 2,70,000/- INR 2,20,000/-
Will work with physician hand to hand
EMI Option NO Yes* Bajaj FinServ.
Genes included in ONCORx for the detection of SNV, insertions and deletions (indels), 
and copy number alterations (CNAs).
ABL1       BRAF          CDKN1A   EPHA3       FGFR4        IKZF1       MCL1         NKX2-1    PMS2   
RNF43    TET2   ACVR1B  BRCA1       CDKN1B   EPHB1      FH                INPP4B  MDM2 
NOTCH1   POLD1        ROS1        TGFBR2     AKT1           BRCA2      CDKN2A  EPHB4   FLCN   
IRF2     MDM4  NOTCH2 POLE      RPTOR    TIPARP   AKT2      BRD4   CDKN2B 
ERBB2  FLT1            IRF4         MED12      NOTCH3    PPARG      SDHA          TNFAIP3 AKT3 
BRIP1            CDKN2C      ERBB3      FLT3           IRS2             MEF2B      NPM1         PPP2R1A SDHB 
TNFRSF14 ALK               BTG1             CEBPA        ERBB4         FOXL2       JAK1            MEN1           NRAS 
PPP2R2A  SDHC           TP53             ALOX12B    BTG2          CHEK1      ERCC4         FUBP1          JAK2 
MERTK        NT5C2          PRDM1         SDHD          TSC1           AMER1     BTK              CHEK2     ERG 
GABRA6   JAK3             MET              NTRK1        PRKAR1A    SETD2      TSC2             APC             C11orf30 
CIC                 ERRFI1        GATA3          JUN              MITF            NTRK2     PRKCI          SF3B1           TYRO3   
AR                  CALR            CREBBP     ESR1          GATA4          KDM5A   MKNK1        NTRK3         PTCH1 
SGK1             U2AF1          ARAF            CARD11       CRKL            EZH2        GATA6         KDM5C        MLH1 
P2RY8   PTEN            SMAD2        VEGFA          ARFRP1       CASP8      CSF1R           FAM46C      GID4 
KDM6A    MPL            PALB2       PTPN11        SMAD4       VHL          ARID1A       CBFB          CSF3R 
FANCA         GNA11          KDR               MRE11A       PARK2       PTPRO      SMARCA4   WHSC1         ASXL1 
CBL               CTCF             FANCC GNA13          KEAP1       MSH2         PARP1        QKI               SMARCB1 
WHSC1L1   ATM            CCND1          CTNNA1  FANCG     GNAQ         KEL             MSH3           PARP2 
RAC1            SMO             WT1             ATR                CCND2         CTNNB1    FANCL        GNAS           KIT     
MSH6          PARP3          RAD21          SNCAIP         XPO1            ATRX         CCND3       CUL3             FAS 
GRM3          KLHL6           MST1R          PAX5           RAD51          SOCS1        XRCC2        AURKA        CCNE1 
CUL4A         FBXW7        GSK3B          KMT2A        MTAP           PBRM1       RAD51B     SOX2          ZNF217 
AURKB        CD22           CXCR4       FGF10           H3F3A          KMT2D       MTOR         PDCD1         RAD51C 
SOX9           ZNF703         AXIN1            CD274          CYP17A1     FGF12         HDAC1        KRAS           MUTYH 
PDCD1LG2  RAD51D       SPEN            AXL              CD70           DAXX           FGF14         HGF           LTK      
MYC              PDGFRA       RAD52       SPOP             BAP1             CD79A          DDR1        FGF19           HNF1A 
LYN                MYCL           PDGFRB      RAD54L      SRC              BARD1          CD79B      DDR2            FGF23 
HRAS           MAF              MYCN           PDK1            RAF1             STAG2          BCL2         CDC73         DIS3 
FGF3           HSD3B1         MAP2K1      MYD88        PIK3C2B     RARA            STAT3        BCL2L1         CDH1 
DNMT3A    FGF4              ID3               MAP2K2       NBN             PIK3C2G      RB1             STK11          BCL2L2 
CDK12        DOT1L           FGF6            IDH1              MAP2K4      NF1              PIK3CA         RBM10       SUFU 
BCL6           CDK4             EED              FGFR1          IDH2           MAP3K1       NF2              PIK3CB        REL  
SYK             BCOR            CDK6           EGFR            FGFR2         IGF1R          MAP3K13     NFE2L2       PIK3R1 
RET             TBX3              BCORL1       CDK8         EP300        FGFR3         IKBKE            MAPK1      NFKBIA 
PIM1          RICTOR     TEK 
Genes for the detection of gene rearrangements:
ALK introns 18, 19    BRCA1 introns 2, 7, 8, 12, 16, 19, 20     ETV4 intron 8   EZR introns 9- 11 
KIT intron 16        MYC intron 1                                                NUTM1 intron 1      RET introns 7-11 
SLC34A2 intron 4   BCL2 3’UTR                                                  BRCA2 intron 2         ETV5 introns 6, 
7FGFR1 intron 1, 5, 17 KMT2A (MLL) introns 6-11                      NOTCH2 intron 26  TERC ncRNA  
PDGFRA introns 7, 9, 11     ROS1 introns 31-35                 BCR introns 8, 13, 14  MSH2 intron 
5CD74 introns 6- 8           ETV6* introns 5, 6                   FGFR2 intron 1, 17         NTRK1 introns 
11RAF1 introns 4-8            RSPO2 intron 1             TERT Promoter             BRAF introns 7-10
EWSR7-introns 7-13      FGFR3 intron 17                      MYB intron 14          NTRK2 Intron 12 
RARA intron 2                   SDC4 intron 2                         TMPRSS2 introns 1- 3
Features of  OncoRx
Intended use: A directional test for tumor profiling and drug decision making of FDA approved therapeutic 
molecules for approved biomarkers, hypothesis-driven translational research and biomarker development.
Biomarkers covered conform OncoKB’s 
• Level1 (FDA approved drugs for FDA approved biomarkers), 
• Level2 (NCCN ratified standard care biomarker response to FDA approved drugs), 
• Level3 (Biomarkers with compelling clinical evidence to FDA Approved or investigational drugs)
• R1 (standard care biomarkers with resistance to FDA approved drugs), 
• R2 (Biomarkers with compelling clinical evidence predictive of resistance to a oncodrug) evidences 
and 
Regions required for Tumor mutation burden-TMB, Microsatellite Instability –MSI assessment (FDA-
approved for selection of solid tumors for treatment with checkpoint inhibition).
Purpose: Assists in predicting outcomes of an FDA approved drug response, resistance, 
immunotherapy selection and management.
Precision and Reporting : High performance standards, regulatory compliance, and quality control are 
ensured with automated protocols and pipelines. 
The test results are represented in 5 parts:
Companion 
diagnostic Supportive Predisposition 
biomarker results evidences with to Resistance to 
with associated full proof therapeutic 
therapy scientific agents Other standard 
indication Other genomic evidences
alterations care biomarkers 
profile-TMB,MSI. with associated 
therapy 
indication 
Biomarkers: Screens 353 potential genes - 174 suitable for characterizing cancer biomarkers with proven 
clinical utilities and an additional 179 high-confidence cancer genes which have emerging evidence in 
ongoing clinical trials.
Coverage: Higher coverage (depth and extent of gene coverage) of 98% of regions of higher complexity.
MSI Markers: MSI (FDA-approved for selection of Fusion coverage: Complete range of fusions with 
solid tumors for treatment with checkpoint multiple fusion partners can be identified in all 
inhibitors) is assessed by National Cancer solid tumors
Institute recommended  Bethesda panel and full 
Rearrangements:  16 potential biomarkers  are 
footprint of other mismatch repair genes such as 
evaluated.
MLH1, MSH2, MSH6 and PMS2.
(ALK, BRAF, CD274, EGFR, ERG, ETV6, NTRK1, RAF, 
Tumor mutation burden (TMB): To identify an 
RET, ROS1, TERT, CD74, FOXA1, NAB2, NRG1, 
individual’s response to immunotherapeutic SLC34A2)
agents such as checkpoint inhibitors, TMB is 
assessed with high precision, considering the Copy number variants (CNVs): 285 biomarkers 
large genome footprint and larger targeted panel screened for CNVs.
size of 3.96 MB with high confidence cancer genes Regulatory regions of MAP2K2, TERT screened. 
enclosed.
Higher cost due to large panel size
Features of  OncoRx Mini
Intended use: Intended for use as a directional test for oncotherapy decision making.
Biomarkers covered conform OncoKB’s 
• Level1 (FDA approved drugs for FDA approved biomarkers), 
• Level2 (NCCN ratified standard care biomarker response to FDA approved drugs), 
• R1 (standard care biomarkers with resistance to FDA approved drugs) candidate genes and 
• MSI (NCI and FDA-approved for selection of solid tumors for treatment with checkpoint inhibition).
Purpose: Assists in predicting outcomes of an FDA approved drug response, resistance, 
immunotherapy selection and management. 
Precision and Reporting : High performance standards, regulatory compliance, and quality control are 
ensured with automated protocols and pipelines.
The test results are represented in 3 parts:
Companion 
diagnostic 
biomarker results Resistance 
with associated profile
therapy 
indication MSI 
profile
Biomarkers: Screens 71 candidate genes - which have the highest level of evidence in oncotherapy and are 
biomarkers for identification of response and resistance to oncotherapeutic agents.
Coverage: Higher coverage of 99% due to targeted candidate gene panel design
MSI Markers: MSI (FDA-approved for treatment of FGFR3- TACC3; 
solid tumors with checkpoint inhibitors) is NTRK1- CD74, EPS15, LMNA, MPRIP, TFG, TPR, 
assessed by biomarkers recommended by the TPM3;
National Cancer Institute,  Bethesda panel. 
NTRK2-ETV6; 
Tumor mutation burden (TMB): TMB cannot be 
assessed considering the targeted and restricted NTRK3- BTBD1, EML4, ETV6, HNRNPA2B1, KANK1, 
panel size. UBE2R2; 
Fusion coverage:  Selective fusions with high PDGFB-COL1A1; 
level of evidence and can be identified with higher PDGFRA- KIF5B; 
confidence in all solid tumors due to screening of 
RET- EML4, TRIM33, KIF5B; 
fusion partners as well.
ROS1-CD74, LIMA1.
R e a r r a n g e m e n t s :  O n c o K B  a p p r o v e d 
rearrangements in 10 potential biomarkers     Copy number variants (CNVs) : 71 biomarkers are 
along with their fusion partners are assessed. assessed.
Rearrangements: Regulatory regions are not covered whereas 
complete exonic and splice site regions are 
ALK-EML4, NPM, RANBP2; screened.
FGFR2- AHCYL1, BICC1 ,PPHLN1,TACC3; 
Lesser cost due to short panel size.
Meet the doctors
Dr. Kalyan Uppaluri is the cofounder Dr. Hima Challa graduated from 
and the owner of K&H Personalized Gandhi Medical College and was 
Medicine Clinic and Research among the top few in her batch. She 
Institute. He did his medical training specialized in Internal Medicine at St. 
at the prestigious Gandhi Medical Joseph Mercy Oakland, Michigan in 
College. He then moved to the the United States. She graduated in 
United States, where he specialized in Medical Genomics from the Ivy 
Internal Medicine at the McLaren league institution of Harvard Medical 
Hospital, Michigan. He also got a School. She also holds a master’s in 
degree in Medical Genomics from Ivy nutrition science from the Texas 
league institute, Stanford University Women University and in integrative 
and pursued cancer research at medicine from the Arizona University. 
Wayne State University, Michigan. 
www.genepowerx.com